[CAR T-cell therapy: Balance of efficacy and safety]

S V Kulemzin; V V Kuznetsova; M Mamonkin; A V Taranin; A A Gorchakov

doi:10.7868/S0026898417020148

[CAR T-cell therapy: Balance of efficacy and safety]

Mol Biol (Mosk). 2017 Mar-Apr;51(2):274-287. doi: 10.7868/S0026898417020148.

[Article in Russian]

Authors

S V Kulemzin¹, V V Kuznetsova¹, M Mamonkin², A V Taranin^{1

3}, A A Gorchakov^{1

3

4}

Affiliations

¹ Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090 Russia.
² Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital and Houston Methodist Hospital, Houston, USA.
³ Novosibirsk State University, Novosibirsk, 630090 Russia.
⁴ [email protected].

PMID: 28537234
DOI: 10.7868/S0026898417020148

Abstract

Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

Keywords: T-cells; adoptive immunotherapy; cancer; chimeric antigen receptor.

Publication types

Review

MeSH terms

Animals
Hematologic Neoplasms* / genetics
Hematologic Neoplasms* / immunology
Hematologic Neoplasms* / therapy
Humans
Immunotherapy / methods*
Oncogene Proteins, Fusion* / genetics
Oncogene Proteins, Fusion* / immunology
Receptors, Antigen, T-Cell* / genetics
Receptors, Antigen, T-Cell* / immunology
T-Lymphocytes* / immunology
T-Lymphocytes* / transplantation

Substances

Oncogene Proteins, Fusion
Receptors, Antigen, T-Cell